Lung Cancer | Exploring the Potential Benefits of Various Adjuvant and Neoadjuvant Therapeutic Ap… [Video]

Featuring perspectives from Drs Jamie Chaft, Solange Peters, Brendan Stiles and Eric Vallieres, including the following topics:

• Effect of the recent practice-changing data sets in the adjuvant and neoadjuvant treatment of non-small cell lung carcinoma (NSCLC) (0:00)

• Case: A woman in her late 60s with Stage IIIA squamous cell carcinoma of the lung and a high level of PD-L1 expression (7:46)

• Strategies to aid shared decision-making in the adjuvant setting for NSCLC (23:43)

• Potential role of circulating tumor DNA to detect minimal residual disease in the adjuvant and neoadjuvant settings (28:06)

• Choosing definitive stereotactic radiosurgery versus sublobar resection in patients with NSCLC (34:53)

• Case: A woman in her early 80s with PD-L1-negative, Stage IIB lung adenocarcinoma with PIK3CA and TP53 mutations and HER2 amplification (37:24)

• Experiences with surgery after neoadjuvant systemic therapy in NSCLC (55:38)

• Case: A woman in her mid-70s with localized pulmonary adenocarcinoma with a MET exon 14 skipping mutation (1:06:23)

• Clinical outcomes from the Phase III CheckMate 816 trial assessing nivolumab in combination with chemotherapy as neoadjuvant therapy for Stage IB-IIIA NSCLC (1:21:36)

• Case: A 48-year-old man with a 3.1-cm, Stage IB NSCLC with an EGFR exon 19 deletion (1:35:20)

• Management of oligometastatic disease with surgery and radiation therapy (1:43:32)

• Numeracy in adjuvant therapy for NSCLC; estimating the benefit to aid patients in therapeutic decision-making (1:49:11)

CME information and select publications (http://m.researchtopractice.com/EarlyStageNSCLC21/Video)